Insmed to Present at 31st Annual J.P. Morgan Healthcare Conference
MONMOUTH JUNCTION, N.J.,
Dec. 13, 2012 /PRNewswire/
-- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical
company focused on developing and commercializing novel, targeted
inhaled therapies for patients with high unmet need who are
battling serious orphan lung diseases, today announced that the
Company will be participating in the 31st Annual J.P.
Morgan Healthcare Conference from January
7-10, 2013 at the Westin St. Francis Hotel in San
Francisco. Will Lewis,
Insmed's President and CEO, will present a corporate overview on
Thursday, January 10th at
1:30 p.m. Pacific time (4:30 p.m. Eastern time).
A live audio webcast of Mr. Lewis' presentation will be made
available in the Investor section of Insmed's website,
http://www.insmed.com where it will be archived for 90 days.
Insmed management will be available for one-on-one meetings with
investors and analysts throughout the conference from January 7-10, 2013. To schedule an
appointment, contact Anne Marie
Fields of LHA at 212-838-3777 or afields@lhai.com or contact
your J.P. Morgan representative.
About Insmed
Insmed Incorporated is a biopharmaceutical company dedicated to
improving the lives of patients battling serious orphan lung
diseases through the development and commercialization of novel,
targeted inhalation therapies in orphan patient populations with
critical unmet needs. Insmed's lead candidate, ARIKACE®,
is engineered to deliver a proven and potent anti-infective
directly to the site of serious lung infections to improve the
efficacy, safety and convenience of treatment for at least two
identified patient populations: cystic fibrosis (CF) patients with
Pseudomonas aeuruginosa lung infections and patients
with nontuberculous mycobacteria lung infections (NTM). Following
positive phase 2 results in CF patients, Insmed's phase 3
registrational study of ARIKACE (CLEAR-108) in Europe and Canada has completed enrollment, and the
Company expects top-line clinical results in mid-2013.
Insmed's U.S. phase 2 clinical trial in NTM (TARGET-NTM) is well
under way with clinical results expected in late 2013. The
Company is currently preparing for regulatory filings and for
commercialization, if and when regulatory approvals are obtained.
For more information, please visit http://www.insmed.com.
Forward-Looking Statements
This release contains forward-looking statements which are made
pursuant to provisions of Section 21E of the Securities Exchange
Act of 1934. Words, and variations of words, such as "intend",
"expect", "will", "anticipate", "believe", "continue", "propose"
and similar expressions are intended to identify forward-looking
statements. Investors are cautioned that such statements in this
release, including statements relating to the status, results and
timing of results of pre-clinical studies and clinical trials and
pre-clinical and clinical data and the anticipated benefits of
Insmed's products, constitute forward-looking statements which
involve risks and uncertainties that could cause actual results to
differ materially from those in the forward-looking statements.
Such risks and uncertainties include, without limitation, failure
or delay of U.S. Food and Drug Administration and other regulatory
reviews and approvals, competitive developments affecting our
product development, delays in product development or clinical
trials, patent disputes involving currently developing products,
unexpected regulatory actions, delays or requests, the failure of
future clinical trials, inability to successfully develop our
product candidates or receive necessary regulatory approvals,
inability to make product candidates commercially successful,
changes in anticipated expenses, and other risks and challenges
detailed in our filings with the U.S. Securities and Exchange
Commission, including our Annual Report on Form 10-K for the year
ended December 31, 2011 and our
Quarterly Report on Form 10-Q for the quarter ended September 30, 2012. Investors are cautioned not
to place undue reliance on any forward-looking statements which
speak only as of the date of this release. We undertake no
obligation to update these forward-looking statements to reflect
events or circumstances or changes in our expectations.
Investor Relations Contact:
LHA
Anne Marie Fields
Senior Vice President
212-838-3777
afields@lhai.com
Bruce Voss
Managing Director
310-691-7100
bvoss@lhai.com
SOURCE Insmed Incorporated